09/06/2026
A meaningful scientific milestone for Papilocare® at the ESGO HPV & Colposcopy Congress in Cappadocia.
During our symposium, “Management of High-Risk HPV Infection: From Watchful Waiting to Intervention in Patients with Low-Grade Cervical Lesions,” we shared new clinical evidence contributing to the evolving management of high-risk HPV infection.
Dr Luis Serrano (Madrid) presented results from three pivotal Papilocare® studies sponsored by Procare Health: PALOMA 1, PALOMA 2 and PAPILOCAN, the new double-blind randomized study versus active control.
Across these studies, results showed a remarkably consistent clinical picture: after 6 months of Papilocare® intensive-regimen therapy, HPV clearance reached approximately 85% in the treatment population — around +30 percentage points versus control, with statistically significant differences between groups.
At 12-month follow-up, the difference between groups was maintained, supporting the persistence of the benefit observed after treatment.
These findings were complemented by independent real-world evidence presented by Prof. Murat Gültekin, Co-Chair of the ESGO Prevention Committee, from a study involving approximately 600 patients, with HPV clearance outcomes consistent with those observed in the pivotal studies.
The symposium was chaired by Dr Maria Kyrgiou, Imperial College London.
Randomized clinical trials, sustained follow-up and independent real-world evidence are converging towards a consistent clinical picture.
And this evidence goes well beyond today’s symposium: the efficacy and safety of Papilocare® have now been assessed and reported in more than 10 manuscripts published in peer-reviewed scientific journals.
Another important step in building and sharing a robust scientific evidence base for the management of high-risk HPV infection and low-grade cervical lesions.
ESGO ESGO ENGAGe
